ArticleOncotarget2016
Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Clinicopathological significance of HSP70 expression in gastric cancer: a systematic review and meta-analysis.BMC gastroenterology · 2021Pooled it
- Heat Shock Proteins as Targets for Cancer Therapeutics.Journal of clinical medicine · 2026Review
- Article
- TRAP1 induced cisplatin resistance in gastric cancer cells by regulating oxidative stress.Frontiers in molecular biosciences · 2025Article
- The Protective Role of Heat Shock Proteins against Stresses in Animal Breeding.International journal of molecular sciences · 2024Review
- Review
- Pre-Conceptional Exposure to Glyphosate Affects the Maternal Hepatic and Ovarian Proteome.Toxicological sciences : an official journal of the Society of Toxicology · 2022Article
- Heat Shock Proteins 27, 70, and 110: Expression and Prognostic Significance in Colorectal Cancer.Cancers · 2021Article
- Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach.Cancers · 2021Article
- Review
- Heat-shock proteins: chaperoning DNA repair.Oncogene · 2020Review
- Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy.Cell death and differentiation · 2020Article
- HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells.Oncogene · 2019Article
- Recent advances in the structural and mechanistic aspects of Hsp70 molecular chaperones.The Journal of biological chemistry · 2019Review
- Tumor suppressor miR-449a inhibits the development of gastric cancerRSC advances · 2018Article
- miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3.International journal of molecular medicine · 2018Article
- Prognostic role of HSPs in human gastrointestinal cancer: a systematic review and meta-analysis.OncoTargets and therapy · 2018Article
- Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis.World journal of gastroenterology · 2017Article
- Article
- Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heat shock protein (HSP) expression is induced by the exposure to stress, such as fever, oxidative stress, chemical exposure, and irradiation. In cancer, HSP promotes the survival of malignant cells by inhibiting the induction of apoptosis. In colorectal cancer, a loss-of-function mutation of HSP110 (HSP110ΔE9) has been identified. HSP110ΔE9 inhibits the nuclear translocation of wild-type HSP110, which is important for its chaperone activity and anti-apoptotic effects. The patients carrying HSP110ΔE9 mutation exhibit high sensitivity to anticancer agents, such as oxaliplatin and 5-fluorouracil. There is still insufficient information about HSP110 localization, the clinicopathological significance of HSP110 expression, and its association with chemotherapy resistance in gastric cancer. Here, we found that high nuclear expression of HSP110 in gastric cancer tissues is associated with cancer progression, poor prognosis, and recurrence after adjuvant chemotherapy. In vitro results showed that HSP110 suppression increases the sensitivity to 5-fluorouracil and cisplatin of human gastric cancer cell lines. Our results suggest that nuclear HSP110 may be a new drug sensitivity marker for gastric cancer and a potential molecular therapeutic target for the treatment of gastric cancer patients with acquired anticancer drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.